Seattle Genetics
1998
FOUNDED
PUBLIC
STATUS
1K-5K
EMPLOYEES
SGEN
STOCK SYMBOL
4
INVESTMENTS
$67.12
SHARE PRICE
(As of Tuesday Closing)
Description
Seattle Genetics is a biotech firm focused on the development of monoclonal antibody-based therapies. The company's lead product, Adcetris, has received approval for advanced frontline, relapsed/refractory and post-consolidation Hodgkin lymphoma, anaplastic large-cell lymphoma, and two other subtypes of cutaneous T-cell lymphoma. The company has several other early-stage programs in trials. Seattle Genetics also licenses its antibody-drug conjugate technology to a number of leading biotechnology and pharmaceutical companies.
Primary Industry
Drug Discovery
Stock Exchange
NAS
Primary Office
- 21823 - 30th Drive South East
- Bothell, WA 98021
- United States
+1 (425) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Seattle Genetics’s full profile, request a free trial.
Seattle Genetics Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $50.71 - $84.37 | $10.8B | $64.38 | -$0.77 | 805K | 161M |
Seattle Genetics Financials Summary
|
In Thousands,
USD |
TTM
31-Mar-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|---|
| Enterprise Value | 11,348,833 | 8,660,695 | 7,104,474 | 6,820,082 |
| Revenue | 709,309 | 654,700 | 482,250 | 418,147 |
| EBITDA | (121,427) | (220,314) | (134,618) | (122,077) |
| Net Income | (124,307) | (222,693) | (125,530) | (140,111) |
| Total Assets | 1,592,604 | 1,503,329 | 877,949 | 838,396 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Seattle Genetics Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Seattle Genetics‘s full profile, request access.
Request full access to PitchBookSeattle Genetics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
This information is reserved for PitchBook Platform users. To explore Seattle Genetics‘s full profile, request access.
Request full access to PitchBookSeattle Genetics Competitors (43)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Genmab | Formerly VC-backed | Copenhagen, Denmark | 000 | 00.000 | 0&0 | |
| 00000000 | Formerly VC-backed | Alameda, CA | 000 | 00000 | 0&0 | |
| 000000000 00000000 | Formerly VC-backed | Zurich, Switzerland | 000 | 00000 | 00000000000 | 00000 |
| 00000 000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 00000000 | 00000 |
| 000000 00000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 00000000000 | 00000 |
Seattle Genetics Investments & Acquisitions (4)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000000 00000000 | 09-Mar-2018 | 000000000000000000 | 00000 | Biotechnology | 0000 0000000 00.0 |
| 0000000-00000 0000 | 01-Oct-2017 | 000000000 00000 00 | 000.00 | Buildings and Property | 0000 0000000 00.0 |
| 00000 00000 000000 | 01-Aug-2017 | 000000000000000000 | 000.00 | Laboratory Services (Healthcare) | 000000 00000 00.0 |
| UNUM Therapeutics | 11-Jun-2015 | Early Stage VC | 0000 | Biotechnology | 0000 0000000 00.0 |
Seattle Genetics Exits (1)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 0000 000000000000 | 11-Jun-2015 | 00000 00000 00 | 0000 | Completed |
|
Seattle Genetics Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore Seattle Genetics‘s full profile, request access.
Request full access to PitchBookSeattle Genetics Executive Team (14)
3 Former Executives
You’re viewing 5 of 14 executives. Get the full list »Seattle Genetics Board Members (3)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Felix Baker Ph.D | Baker Bros. Advisors | Board Member | 000 0000 |
2 Former Board Members
You’re viewing 1 of 3 board members. Get the full list »